Cargando…

Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery

The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are available, there have been no systematic comparisons of their barrier properties with respect to drug permeability. We com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellinen, Laura, Hongisto, Heidi, Ramsay, Eva, Kaarniranta, Kai, Vellonen, Kati-Sisko, Skottman, Heli, Ruponen, Marika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076505/
https://www.ncbi.nlm.nih.gov/pubmed/32093035
http://dx.doi.org/10.3390/pharmaceutics12020176
_version_ 1783507232532463616
author Hellinen, Laura
Hongisto, Heidi
Ramsay, Eva
Kaarniranta, Kai
Vellonen, Kati-Sisko
Skottman, Heli
Ruponen, Marika
author_facet Hellinen, Laura
Hongisto, Heidi
Ramsay, Eva
Kaarniranta, Kai
Vellonen, Kati-Sisko
Skottman, Heli
Ruponen, Marika
author_sort Hellinen, Laura
collection PubMed
description The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are available, there have been no systematic comparisons of their barrier properties with respect to drug permeability. We compared the barrier properties of several RPE secondary cell lines (ARPE19, ARPE19mel, and LEPI) and both primary (hfRPE) and stem-cell derived RPE (hESC-RPE) cells by investigating the permeability of nine drugs (aztreonam, ciprofloxacin, dexamethasone, fluconazole, ganciclovir, ketorolac, methotrexate, voriconazole, and quinidine) across cell monolayers. ARPE19, ARPE19mel, and hfRPE cells displayed a narrow P(app) value range, with relatively high permeation rates (5.2–26 × 10(−6) cm/s. In contrast, hESC-RPE and LEPI cells efficiently restricted the drug flux, and displayed even lower P(app) values than those reported for bovine RPE-choroid, with the range of 0.4–32 cm(−6)/s (hESC-RPE cells) and 0.4–29 × 10(−6) cm/s, (LEPI cells). Therefore, ARPE19, ARPE19mel, and hfRPE cells failed to form a tight barrier, whereas hESC-RPE and LEPI cells restricted the drug flux to a similar extent as bovine RPE-choroid. Therefore, LEPI and hESC-RPE cells are valuable tools in ocular drug discovery.
format Online
Article
Text
id pubmed-7076505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70765052020-03-20 Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery Hellinen, Laura Hongisto, Heidi Ramsay, Eva Kaarniranta, Kai Vellonen, Kati-Sisko Skottman, Heli Ruponen, Marika Pharmaceutics Article The retinal pigment epithelial (RPE) cell monolayer forms the outer blood–retinal barrier and has a crucial role in ocular pharmacokinetics. Although several RPE cell models are available, there have been no systematic comparisons of their barrier properties with respect to drug permeability. We compared the barrier properties of several RPE secondary cell lines (ARPE19, ARPE19mel, and LEPI) and both primary (hfRPE) and stem-cell derived RPE (hESC-RPE) cells by investigating the permeability of nine drugs (aztreonam, ciprofloxacin, dexamethasone, fluconazole, ganciclovir, ketorolac, methotrexate, voriconazole, and quinidine) across cell monolayers. ARPE19, ARPE19mel, and hfRPE cells displayed a narrow P(app) value range, with relatively high permeation rates (5.2–26 × 10(−6) cm/s. In contrast, hESC-RPE and LEPI cells efficiently restricted the drug flux, and displayed even lower P(app) values than those reported for bovine RPE-choroid, with the range of 0.4–32 cm(−6)/s (hESC-RPE cells) and 0.4–29 × 10(−6) cm/s, (LEPI cells). Therefore, ARPE19, ARPE19mel, and hfRPE cells failed to form a tight barrier, whereas hESC-RPE and LEPI cells restricted the drug flux to a similar extent as bovine RPE-choroid. Therefore, LEPI and hESC-RPE cells are valuable tools in ocular drug discovery. MDPI 2020-02-19 /pmc/articles/PMC7076505/ /pubmed/32093035 http://dx.doi.org/10.3390/pharmaceutics12020176 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hellinen, Laura
Hongisto, Heidi
Ramsay, Eva
Kaarniranta, Kai
Vellonen, Kati-Sisko
Skottman, Heli
Ruponen, Marika
Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title_full Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title_fullStr Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title_full_unstemmed Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title_short Drug Flux Across RPE Cell Models: The Hunt for An Appropriate Outer Blood–Retinal Barrier Model for Use in Early Drug Discovery
title_sort drug flux across rpe cell models: the hunt for an appropriate outer blood–retinal barrier model for use in early drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076505/
https://www.ncbi.nlm.nih.gov/pubmed/32093035
http://dx.doi.org/10.3390/pharmaceutics12020176
work_keys_str_mv AT hellinenlaura drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT hongistoheidi drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT ramsayeva drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT kaarnirantakai drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT vellonenkatisisko drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT skottmanheli drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery
AT ruponenmarika drugfluxacrossrpecellmodelsthehuntforanappropriateouterbloodretinalbarriermodelforuseinearlydrugdiscovery